Aligarh: A team of Aligarh Muslim University-AMU faculty members and superannuated diabetes and endocrinology expert comprising Department of Statistics and Operations Research educators, Dr. Faiz Noor Khan Yusufi and Prof Aquil Ahmed, Chairman, and Prof Jamal Ahmad, Retired former Director of Rajiv Gandhi Centre for Diabetes and Endocrinology, JN Medical College, have developed a novel system that predicts heart diseases for Type-2 Diabetic patients.
Their innovation, ‘System and Method for Dual Model-Based Early Prediction of Heart Disease for Indian Type-2 Diabetes Mellitus Patients’ which has been recently patented by The Commissioner of Patents, Australian Government will augment the capabilities of cardiologists and endocrinologists in predicting future cardiac problems in diabetic people—making way for early restorative remedies to prevent heart complications in such patients.
Speaking on the efficacy of the invention, Prof Aquil Ahmed said, “In this invention, two risk prediction models have been developed that predict the five-year incidence probabilities of heart disease complications caused by Type-2 Diabetes”.
He added: “The innovation is all the more important in today’s world amid the growing concerns over more diabetic people developing cardiac problems and when scientists across the globe are focussing on preventive technologies that ultimately reveal how cardiovascular diseases progress over time”.
“This model will assist both the doctors and patients in regularly monitoring heart diseases, reducing the risk of death and hospitalization from a cardiac cause. The invention also offers a new possibility for diabetes care and provides a cheap and financially reasonable alternative to managing the disease”, said Dr. Faiz Noor Khan Yusufi.
Prof Jamal Ahmad pointed out: “At a time when we still have a long way to go to involve Artificial Intelligence and Machine Learning in the prediction of heart diseases; this invention will certainly change the way people think about heart ailments. It will facilitate the assessment of long-term therapies, and help clinicians monitor treatment responses for Type-2 diabetic people”.